Finoriq research workspace
AtaiBeckley Inc. (ATAI) SEC Filings & Filing Highlights
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research. Review ATAI SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
- Company
- AtaiBeckley Inc. (ATAI)
- Ticker
- ATAI
- Market Cap
- $2.6B
- Latest Price
- $7.185
- Industry
- Biotech & Pharma
AtaiBeckley Inc. (ATAI) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AtaiBeckley Inc. (ATAI).
| Event | Form | Date |
|---|---|---|
| Broker Non-votesOn June 4, 2026, AtaiBeckley Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). As of April 9, 2026, the... | 8-K5.07 | 2026-06-08 |
| Jefferies Global Healthcare ConferenceAs previously announced, AtaiBeckley (the “Company”) will participate in multiple upcoming investor conferences in June 2026, as set forth... | 8-K7.01 | 2026-06-03 |
| AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Upda...AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update | 8-K2.02 | 2026-05-12 |
| AtaiBeckley Inc.: Material agreementOn March 6, 2026, AtaiBeckley Inc. (the “Company”) entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC... | 8-K1.01 | 2026-03-09 |
| AtaiBeckley Inc.: Corporate updateOn June 2, 2025, atai Beckley N.V. (“atai”, f/k/a atai Life Sciences N.V.) entered into a share purchase agreement with Beckley Psytech Lim... | 8-K8.01 | 2026-03-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.